Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer

Nat Commun. 2021 May 27;12(1):3199. doi: 10.1038/s41467-021-23394-4.

Abstract

In patients with metastatic cancer, spatial heterogeneity of somatic alterations may lead to incomplete assessment of a cancer's mutational profile when analyzing a single tumor biopsy. In this study, we perform sequencing of cell-free DNA (cfDNA) and distinct metastatic tissue samples from ten rapid autopsy cases with pre-treated metastatic cancer. We show that levels of heterogeneity in genetic biomarkers vary between patients but that gene expression signatures representative of the tumor microenvironment are more consistent. Across nine patients with plasma samples available, we are able to detect 62/62 truncal and 47/121 non-truncal point mutations in cfDNA. We observe that mutation clonality in cfDNA is correlated with the number of metastatic lesions in which the mutation is detected and use this result to derive a clonality threshold to classify truncal and non-truncal driver alterations with reasonable specificity. In contrast, mutation truncality is more often incorrectly assigned when studying single tissue samples. Our results demonstrate the utility of a single cfDNA sample relative to that of single tissue samples when treating patients with metastatic cancer.

Publication types

  • Evaluation Study

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Autopsy / methods*
  • Biomarkers, Tumor / genetics
  • Chemoradiotherapy, Adjuvant
  • Circulating Tumor DNA / genetics*
  • Cohort Studies
  • DNA Copy Number Variations
  • DNA Mutational Analysis / methods*
  • Exome Sequencing
  • Female
  • Genetic Heterogeneity
  • Humans
  • Male
  • Neoadjuvant Therapy
  • Neoplasms / blood
  • Neoplasms / diagnosis*
  • Neoplasms / pathology
  • Neoplasms / therapy
  • Point Mutation
  • RNA-Seq
  • Reference Values
  • Sensitivity and Specificity
  • Spatial Analysis
  • Time Factors
  • Tumor Microenvironment / genetics*

Substances

  • Biomarkers, Tumor
  • Circulating Tumor DNA